Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz in Metastatic Castration-Refractory Prostate Cancer
NCT00964002Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- May 2008
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efavirenz in prostate cancer (PCa), sponsored by Institut Bergonié. Primary endpoint: Percentage of Participants Without Prostate-specific Antigen Progression at 3 months. Started May 2008; status: completed.
02
Drugs
efavirenz
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00964002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00964002.